Zobrazeno 1 - 10
of 19
pro vyhledávání: '"Daniel A. Gipe"'
Autor:
Yi Zhang, Robert Pordy, Alberico L. Catapano, Vladimir Son, Evelyn Gasparino, Shazia Ali, Daniel A. Gipe, Mariko Harada-Shiba
Publikováno v:
Atherosclerosis. 314:33-40
Evinacumab, an angiopoietin-like protein 3 monoclonal antibody, reduced low-density lipoprotein cholesterol (LDL-C) significantly in a Phase 2 study of patients with homozygous familial hypercholesterolemia. In this double-blind, placebo-controlled P
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::97bea8283b826bcd9e9643acffb82af8
https://doi.org/10.1016/j.atherosclerosis.2020.10.013
https://doi.org/10.1016/j.atherosclerosis.2020.10.013
Autor:
Aurelie Bouzelmat, Hayes Dansky, Richard L. Dunbar, Daniel A. Gipe, Robert Pordy, Scott Mellis, Poulabi Banerjee, Kuo Chen Chan, Sara Hamon, Zahid Ahmad, William J. Sasiela
Publikováno v:
Circulation
Supplemental Digital Content is available in the text.
Background: Hypertriglyceridemia is associated with increased cardiovascular risk and may be caused by impaired lipoprotein clearance. Angiopoietin-like protein 3 (ANGPTL3) inhibits lipoprot
Background: Hypertriglyceridemia is associated with increased cardiovascular risk and may be caused by impaired lipoprotein clearance. Angiopoietin-like protein 3 (ANGPTL3) inhibits lipoprot
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b6ea5de88d5f8cc91b3be7a90ac7adfe
http://europepmc.org/articles/PMC6686956
http://europepmc.org/articles/PMC6686956
Autor:
John S. Millar, Laurens F. Reeskamp, Hans Jansen, Geesje M. Dallinga-Thie, G. Kees Hovingh, Dewi van Harskamp, Henk Schierbeek, Liya Wu, Daniel J. Rader, Daniel A. Gipe, Marina Cuchel
Publikováno v:
Arteriosclerosis, thrombosis, and vascular biology, 41(5), 1753-1759. Lippincott Williams and Wilkins
Arteriosclerosis, Thrombosis, and Vascular Biology
Arteriosclerosis, Thrombosis, and Vascular Biology
Supplemental Digital Content is available in the text.
Objective: The mechanism by which evinacumab, a fully human monoclonal antibody directed against ANGPTL3 (angiopoietin-like 3 protein) lowers plasma LDL (low-density lipoprotein) cholesterol
Objective: The mechanism by which evinacumab, a fully human monoclonal antibody directed against ANGPTL3 (angiopoietin-like 3 protein) lowers plasma LDL (low-density lipoprotein) cholesterol
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ec4dc1aa039b5083495d1d137d28d579
https://pure.amc.nl/en/publications/angptl3-inhibition-with-evinacumab-results-in-faster-clearance-of-idl-and-ldl-apob-in-patients-with-homozygous-familial-hypercholesterolemia--brief-report(229b8efd-fcc3-485c-8d8f-449c0e5cbabd).html
https://pure.amc.nl/en/publications/angptl3-inhibition-with-evinacumab-results-in-faster-clearance-of-idl-and-ldl-apob-in-patients-with-homozygous-familial-hypercholesterolemia--brief-report(229b8efd-fcc3-485c-8d8f-449c0e5cbabd).html
Autor:
Alex Lopez, Jerome I. Rotter, Yii-Der Ida Chen, Lukas Habegger, Anders Berg Wulff, Richard L Dunbar, John Penn, Anita M. van den Hoek, An Zhao, Omri Gottesman, Cristopher V. Van Hout, Scott M. Damrauer, Tanya M. Teslovich, Aurelie Bouzelmat, Daniel J. Rader, Poulabi Banerjee, David J. Carey, Viktoria Gusarova, Shane McCarthy, Frederick E. Dewey, Kae-Woei Liang, David H. Ledbetter, Gary Herman, Rick Zhang, Alan R. Shuldiner, Svati H. Shah, Claudia Schurmann, Neil Stahl, Marylyn D. Ritchie, Sara Hamon, Colm O'Dushlaine, Ingrid B. Borecki, Daniel A. Gipe, Jesper Gromada, Hans M.G. Princen, Børge G. Nordestgaard, H. Lester Kirchner, Michael F. Murray, Shannon Bruse, Aris Baras, Jeffrey G. Reid, Wayne H-H Sheu, William E. Kraus, Xiuqing Guo, Aeron Small, Brad Shumel, William J. Sasiela, Anne Tybjærg-Hansen, Andrew J. Murphy, Joseph B. Leader, John D. Overton, Robert Pordy, Scott Mellis, Weiping Shao, George D. Yancopoulos, Hayes Dansky, I-Te Lee
Publikováno v:
New England Journal of Medicine. 377:211-221
BackgroundLoss-of-function variants in the angiopoietin-like 3 gene (ANGPTL3) have been associated with decreased plasma levels of triglycerides, low-density lipoprotein (LDL) cholesterol, and high-density lipoprotein (HDL) cholesterol. It is not kno
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4441c06965afc71c8400abc055096be3
https://doi.org/10.1056/nejmoa1612790
https://doi.org/10.1056/nejmoa1612790
Autor:
Albert Torri, Daniel A. Gipe, Robert Dufour, Robert Pordy, Feng Yang, Daniel Gaudet, Zhizhi Qing, Robert E. Weiss, Jean Bergeron, Matthew Andisik, G. Kees Hovingh
Publikováno v:
International journal of cardiology, 228, 754-760. Elsevier Ireland Ltd
Background PCSK9 inhibition with alirocumab significantly reduced LDL-C levels in trials of up to 78weeks' duration in patients with heterozygous familial hypercholesterolemia (HeFH). We report results from 3years of an ongoing open-label treatment e
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d48d96d7add5b3a1e172781fba22b486
https://doi.org/10.1016/j.ijcard.2016.11.046
https://doi.org/10.1016/j.ijcard.2016.11.046
Autor:
Ana Catarina Alves, Robert Pordy, Kepa B. Uribe, Kuo-Chen Chan, Michel Tarabocchia, Mafalda Bourbon, Poulabi Banerjee, Daniel Gaudet, Paul J. Skiba, César Martín, Asier Benito-Vicente, Daniel A. Gipe
Publikováno v:
Addi. Archivo Digital para la Docencia y la Investigación
instname
Arteriosclerosis, Thrombosis, and Vascular Biology
instname
Arteriosclerosis, Thrombosis, and Vascular Biology
Supplemental Digital Content is available in the text.
Objective: Homozygous familial hypercholesterolemia is a rare disease usually caused by LDLR (low-density lipoprotein receptor) mutations. Homozygous familial hypercholesterolemia is charact
Objective: Homozygous familial hypercholesterolemia is a rare disease usually caused by LDLR (low-density lipoprotein receptor) mutations. Homozygous familial hypercholesterolemia is charact
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8528f37686a4b14acf4d8f9a7a2c7468
http://hdl.handle.net/10810/39123
http://hdl.handle.net/10810/39123
Autor:
Daniel A. Gipe, Alberico L. Catapano, Mariko Harada-Shiba, Robert Pordy, Shazia Ali, Vladimir Son, Evelyn Gasparino
Publikováno v:
Journal of Clinical Lipidology. 14:581
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1419d26080a3206d71af14b527a9047f
https://doi.org/10.1016/j.jacl.2020.05.061
https://doi.org/10.1016/j.jacl.2020.05.061
Autor:
Frederick J. Raal, Shazia Ali, Seth J. Baum, John J.P. Kastelein, Daniel Gaudet, Robert S. Rosenson, Robert Pordy, Poulabi Banerjee, Kuo-Chen Chan, Daniel A. Gipe, Laurens F. Reeskamp
Publikováno v:
Journal of Clinical Lipidology. 14:552
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bafceb83ef4f50aa6dcf9a2233bc8fe2
https://doi.org/10.1016/j.jacl.2020.05.019
https://doi.org/10.1016/j.jacl.2020.05.019
Autor:
Eli M. Roth, James M. McKenney, Robert Dufour, Richard Wu, Michael J. Koren, Anne-Catherine Ferrand, Daniel A. Gipe, Corinne Hanotin
Publikováno v:
Postgraduate Medicine. 127:125-132
Alirocumab, a fully human monoclonal antibody to proprotein convertase subtilisin/kexin type 9, is in Phase III development for the treatment of hypercholesterolemia. In Phase II studies, 150 mg every 2 weeks (Q2W) was the highest Q2W dose studied, a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f25f2a879a59f66ce99d5d6eb9748bc6
https://doi.org/10.1080/00325481.2015.998987
https://doi.org/10.1080/00325481.2015.998987
Autor:
G.K. Hovingh, Daniel Gaudet, Daniel A. Gipe, K.Y. Chyu, Robert Pordy, Marina Cuchel, Etienne Khoury, Kuo-Chen Chan, Z. Ahmad, William J. Sasiela, Parth K. Shah
Publikováno v:
European Heart Journal. 38
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9224d943d65fc7164e13893db522dfda
https://doi.org/10.1093/eurheartj/ehx493.5938
https://doi.org/10.1093/eurheartj/ehx493.5938